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ABSTRACT 
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system 
(CNS) that arises from a combination of a complex genetic predisposition and environmental 
factors. For northern Europeans, the lifetime risk of MS is 1:400, making it the most common 
non-traumatic cause of disability in young adults. The strongest genetic associations with MS 
are located within the human leukocyte antigen (HLA) complex and in recent years, a large 
number of non-HLA risk loci that influence disease susceptibility have been identified. The 
contribution of lifestyle and environmental factors is more difficult to study. However, it is 
important to identify these factors since they are potentially preventable and may also lead to 
hypotheses on critical pathogenic events.  
This thesis focuses on the impact of tobacco on MS risk. We replicated the finding of an 
association between smoking and MS risk and demonstrated that the risk of developing the 
disease increases with cumulative dose of smoking. However, snuff use, which leads to 
exposure to high doses of nicotine, was associated with decreased MS risk (paper I). In paper 
II, we showed an inverse dose-response correlation between cumulative dose of snuff use and 
disease risk. Nicotine has been shown to be protective in several models of inflammatory 
diseases, and may thus exert anti-inflammatory and immune-modulating effects in a way that 
reduces the risk of developing MS. 
In paper IV, we investigated the association between smoking and MS in more detail. Both 
duration and intensity of smoking contribute independently to the risk of developing the 
disease. Smoking affects MS risk regardless of age at exposure, in contrast to many other 
environmental risk factors which seem to act mainly during adolescence. The detrimental 
effect of smoking slowly abates after smoking cessation regardless of the timing of smoking 
and regardless of the cumulative dose of smoking.  
In paper III, we demonstrated that exposure to passive smoking among never smokers is 
associated with increased risk of MS. 
Tobacco smoke, but not tobacco consumption in the form of moist snuff, increases MS risk, 
suggesting that the critical effects of smoking may be caused by irritation in the lungs. 
Smoking increases pro-inflammatory cell activation and induces post-translational 
modifications of proteins in the lungs. In paper V, an interaction was demonstrated between 
carriage of HLA-DRB1*15, absence of HLA A*02, and smoking in the development of MS. 
We hypothesize that smoke-induced lung irritation, in the context of MS risk HLA genes, 
may generate post-translationally modified peptides which are cross-reactive with CNS 
antigens, promoting a CNS-directed autoaggressive immunity that results in MS. Further 
studies would be valuable in order to investigate whether other forms of lung irritation 
contribute to the triggering of MS.  
Apart from generating data of importance for preventive measures, our finding of an 
interaction between smoking and HLA genotype emphasizes the need to include data on 
environmental exposures in genetic analyses of complex diseases and vice versa. 
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1 INTRODUCTION 
 
1.1 MULTIPLE SCLEROSIS 
MS is an inflammatory disease of the central nervous system, characterized by myelin 
destruction, axonal degeneration and sclerotic plaques
1
. Approximately 2.5 million people are 
estimated to suffer from MS worldwide. In Sweden, the prevalence of MS has been estimated 
to be 188.9/100,000, with a female-to-male ratio of approximately 2.35:1
2
. The disease 
occurs with an annual incidence of approximately 5/100,000. 
MS typically starts as a relapsing remitting disease (RR MS) characterized by bouts of 
disease activity between periods of remission. The symptoms vary considerably depending on 
the location of the lesions within the CNS. During relapses, patients commonly experience 
symptoms from the motor, sensory, visual and autonomic systems. A relapse usually appears 
in a sub-acute manner over days or weeks followed by a gradual decline of the symptoms 
over weeks to months. Many lesions are clinically silent and magnetic resonance imaging 
(MRI) studies have indicated that lesions appear seven to ten times more frequently than 
clinical relapses. Ultimately the disease usually converts into secondary progressive MS 
(SPMS) with gradually increasing disability. In a low proportion of people affected by MS, 
the disease is progressive from onset without preceding clinically recognizable relapses 
(primary progressive MS; PPMS) (figure 1).  
Figure 1. Common disease phenotypes of MS. 
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The diagnosis of RRMS is based on relapse history, findings on MRI and exclusion of 
differential diagnoses. The first neurological manifestation is usually referred to as a 
clinically isolated syndrome (CIS). For an MS diagnosis to be made according to the 
McDonald criteria a second event, separate in time or space, is required. A diagnosis of 
PPMS is based on clinical history, MRI findings, and cerebrospinal examination
3
.  
The therapeutic options for MS have expanded in the past two decades. Several disease-
modifying treatments are available today that reduce the number of clinical relapses and 
lesions seen by MRI, and oral compounds have recently been introduced.  The first-line 
treatment of MS includes interferon-beta products and glatiramer acetate, which have similar 
long-term efficacy
4-5
. However, neutralizing antibodies to interferon β products may develop 
during treatment and reduce clinical efficacy
6
. When first-line drugs fail to suppress disease 
activity or in cases of high disease activity at onset, second-line treatments may be used. 
These include intravenously administered monoclonal antibodies directed against lymphocyte 
surface molecules
7
, and orally taken immunomodulatory drugs
8-9
. Most of the second-line 
drugs act broadly on the immune system with potentially serious side effects.  
 
1.2 THE ETIOLOGY OF MS 
Numerous studies have shown that MS is a complex disease in which both genetic and 
environmental factors contribute to disease susceptibility. The concordance rate has 
previously been estimated to be around 30% for monozygotic twins and approximately 7% 
for dizygotic twins
10
. Recent population based studies have given more certain and lower 
estimates of heritability, with age adjusted concordance rates of about 17 % for monozygotic 
twins, as opposed to about 2 % for dizygotic twins and siblings in general
11
. The substantially 
increased risk of developing MS in relatives of affected individuals gives a solid base for 
gene variants contributing to susceptibility, whereas the monozygotic concordance rates of 
about 17% is a strong argument for an important role of lifestyle and environmental factors in 
determining the risk of MS.  
 
1.2.1 Genetics 
As in most organ specific inflammatory diseases of suspected auto-immune origin, the 
strongest genetic associations with MS are located within the human leukocyte antigen 
(HLA) complex (figure 2). The association between the HLA gene complex and MS was first 
described in 1972
12
. The full sequence of the region was completed in 1999. Determining the 
role that specific HLA genes play in MS has been difficult since genes in this region are often 
passed down in tightly linked combinations, making it difficult to distinguish their individual 
effects. The proportion of specific HLA alleles differs between ethnic groups. The HLA 
complex contains around 200 genes, the vast majority coding for proteins involved in 
immune function. In organ specific inflammatory diseases, the HLA class I- and class II-
encoded molecules are of particular importance. These are cell-surface glycoproteins that 
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display and present short antigenic peptide fragments to specific T-cells which can then 
become activated by a second stimulatory signal and initiate an immune response. Class I 
molecules present peptides to CD8+ T cells, whereas class II molecules present peptides to 
CD4+ T cells. The class II allele HLA-DRB1*15 increases the risk of developing MS in 
almost all populations, with an odds ratio (OR) around 3
13
. Other HLA-DRB1 alleles have 
recently been independently associated with MS risk
14
. Genes in the class I region have also 
been implicated in MS, such as the class I allele HLA-A*02, which has a protective effect in 
many populations with an OR of approximately 0.7
15-17
.  
Figure 2. The HLA complex 
 
  
 
 
Genome-wide association studies (GWAS) have identified a large number of gene regions 
outside the HLA complex that influence disease susceptibility. These studies have, at this 
moment, unequivocally uncovered associations with over a 100 susceptibility loci
18-19
. Each 
of the non-HLA locus has a smaller impact on MS risk with ORs less than 1.2. Furthermore, 
it is possible that a number of rare variants or susceptibility loci with effect sizes below the 
significance threshold in GWAS may contribute to the disease. Most of the disease-
associated non-HLA genes are involved in regulating immune functions, which suggests that 
the critical disease mechanism involves immunological pathways. Despite the large number 
of gene loci associated with MS risk, they only explain a fraction of the heritability. One of 
several potential reasons for the missing heritability is interactions between risk genes and 
lifestyle/environmental factors. 
 
1.2.2 Environment and lifestyle 
Migration studies have shown that when people move from a high- to a low-risk area in 
childhood this reduces the risk of MS to an intermediate level, between the level of their birth 
country and that of their final residence. Migration in the opposite direction does not 
consistently increase the risk of MS until the next generation whose risk is close to that of 
their birthplace
20-21
. These data suggest that environmental exposures during childhood and 
adolescence are of essential importance for disease risk.  
Lifestyle factors and environmental exposures are more difficult to study than genetic factors. 
However, it is important to identify these factors since they, as opposed to risk genes, are 
potential targets for prevention. Environmental factors that have been repeatedly shown to be 
associated with the risk of MS are sun exposure habits and vitamin D status, Epstein-Barr 
virus (EBV) infection and mononucleosis (IM), adolescent body-mass index (BMI), and 
smoking.  
 10 
 
1.2.2.1 Sun-exposure habits and vitamin D 
Both the incidence and prevalence of MS increase with the distance from the equator (figure 
3). Latitudinal gradients have been identified throughout the world including Europe, North 
America, Australia, and New Zeeland
22
. It has been suggested that this latitude-dependent 
gradient in MS occurrence is caused by less exposure to sunlight or decreased levels of 
vitamin D
23
.  
Figure 3. The prevalence of MS associated with latitude.  
 
There is evidence suggesting that frequent exposure to ultraviolet radiation (UVR) confers a 
protective effect against developing MS
24-26
, and vitamin D has been proposed to be the 
major mediator of this protective effect
27-28
. The intensity of UVR exposure varies with 
latitude and season, and lower intensity of UVR in winter may be insufficient to support 
vitamin D synthesis in some locations
29
. Vitamin D is involved in the regulation of the 
immune system by binding to vitamin D response elements in the regulatory region of 
immune genes
30-31
. Furthermore, in several GWAS and candidate studies, an association has 
been observed between MS risk and markers in the CYP27B1 and CYP24A1 genes, the latter 
of which encodes an enzyme involved in vitamin D metabolism
32-33
.  
However, it has been observed that low levels of sun exposure may have an impact on MS 
risk even after adjustment for vitamin D status, suggesting that the association between sun 
exposure and MS risk cannot be fully explained by vitamin D-mediated mechanisms
34
. 
 
There are a number of pathways whereby UVR may affect immune functions that are 
independent of vitamin D production
35
. UVB appears to up-regulate the secretion of TNF-a, 
IL-10, and regulatory T-cells
36
, and UVA radiation has a complex dose-related 
immunomodulating effect where the underlying mechanism is not fully investigated. In 
experimental autoimmune encephalomyelitis (EAE) studies, UVB exposure influenced 
systemic immune reactions and attenuated systemic autoimmunity via the induction of skin-
derived tolerogenic dendritic cells and regulatory T cells
37
. Vitamin D status may thus not be 
the only mediator of a latitude effect related to UVR exposure. 
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Another aspect discussed in the context of UVR and vitamin D is when insufficient exposure 
exerts its effect on the risk for MS, and if there is an interaction with MS risk genes. Several 
reports of a month of birth effect (MOB) have been published
38-39
. Children born in the spring 
in the northern hemisphere run an increased MS risk later in life. However, the authors of a 
recent study suggest that the claims of an association between MS and MOB may be false 
positive due to inadequate control for confounding factors
40
. In our own studies of vitamin D 
status of newborn, there was no difference in vitamin D status between those who later 
developed MS and matched controls
41
.  
Childhood and adolescence may be the most critical period for insufficient exposure. In an 
EAE study, vitamin D supplementation in the adolescent period improved the disease 
outcome whereas the same supplementation regimen had no influence when the 
administration took place during pre- and postnatal development or in adult age
42
.  
An interaction with the HLA locus has been suggested
43
. However, we found no such 
interaction in our case control cohort
34
. 
 
1.2.2.2 Epstein-Barr virus infection and mononucleosis  
EBV infection is usually asymptomatic in childhood, and in countries where MS is rare, early 
infection with EBV is almost universal. However, in countries where primary infection is 
delayed beyond the early years of childhood and the infection more commonly results in IM, 
the prevalence of MS is high. Several studies have examined the association between IM and 
MS, with consistent results. People who have had IM have about a twofold increased risk of 
developing MS compared to those who were infected during childhood, whereas people who 
remain uninfected with EBV have an extremely low risk of developing the disease
44-45
. A 
meta-analysis of eight published studies found that the overall OR for MS was 13.5 (95% CI 
6.3-31.4) when comparing EBV-seropositive and EBV-seronegative people
46
. 
By measuring anti-EBV titers before and after MS onset in 305 cases, Levin et al 
demonstrated that 100% of MS cases that were initially EBV seronegative had seroconverted 
prior to MS onset
47
. Several studies have observed a significant increase in antibody titers 
many years prior to MS onset
46, 48-49
. Nielsen et al found that the increased risk of MS 
following IM is independent of age, gender and infection severity, and may persist for 
decades
50
. The consistent findings that EBV infection and elevation of anti-EBNA antibody 
titers precede MS onset suggest that EBV may be a necessary factor in MS development.  
Data from several studies suggest that HLA status and either IM or high anti-EBV titers 
synergistically increase the risk of MS
51-52
. In the largest study on this topic, those who were 
positive for HLA-DRB1*15, negative for HLA-A*02 and with high EBNA:385-420 titers 
had a 16-fold higher risk of MS than those who did not carry any of these factors
52
. The 
observed interaction between HLA status and anti-EBV titers suggests that the mechanism 
through which HLA genes influence the risk of MS may involve the immune control of 
EBV infection. However, it cannot be completely ruled out that a dysregulated 
immunological response to EBV infection may be a consequence of the underlying 
 12 
 
pathophysiology and genetic predisposition of MS. 
 
1.2.2.3 Smoking habits and exposure to passive smoking 
The first detected association between smoking and MS risk was reported in the 1960s
53
. 
However, other studies found no impact of smoking on MS risk
54
.  In the 1990s, smoking 
was found to be associated with MS risk in two prospective cohort studies
55
. Several studies 
investigating the link between smoking and MS susceptibility have been published during the 
last decade and almost all have detected a significant detrimental effect
56-59
. In a study using 
banked blood samples, Sundström et al found that cotinine levels, indicating recent exposure 
to tobacco smoke, were increased in MS cases compared with controls
60
. There is also 
evidence of a dose-response correlation between cumulative dose of smoking and the risk of 
developing the disease
59
. 
Data has been inconsistent regarding the influence of passive smoking. A French case-control 
study found an association between exposure to parental smoking at home and early onset 
MS
61
. The risk increased with longer duration of exposure. However, no effect of maternal 
smoking during pregnancy on MS risk in offspring has been observed
62-63
. In the study by 
Montgomery et al
62
, information regarding maternal smoking during pregnancy was recorded 
prospectively, thus eliminating the problems associated with differential reporting bias. 
However, many women who smoke during pregnancy inaccurately report themselves as non-
smokers
64-65
. Furthermore, maternal smoking during pregnancy may not be a sufficiently 
sensitive measure of later parental smoking at home.  
The molecular pathways responsible for the association between smoking and MS are not yet 
known, but several plausible hypotheses regarding the mechanism have been put forward. 
Both humoral and cell-mediated immunity are affected by smoking
66
, and smokers have 
increased levels of important markers of inflammation such as C-reactive protein and 
Interleukin (IL)-6
67
. Serum concentrations of cyanide are strongly correlated with the level of 
tobacco consumption, and chronic cyanide intoxication may lead to widespread 
demyelination
68-69
. Some evidence points to a potential role of the free radical nitric oxide. 
Exposure to nitric oxide has been shown to cause axonal degeneration or block axonal 
conduction
70-71
. Finally, smoking may increase the risk of MS by increasing the frequency 
and persistence of respiratory infections.  
 
1.2.2.4 Other environmental factors 
Other lifestyle or environmental factors that have been associated with MS are high BMI in 
adolescence
72-73
, shift work
74
, and exposure to organic solvents
75
, among others.  
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1.3 THE PATHOPHYSIOLOGY OF MS 
The main function of the immune system is to protect the host from harmful pathogens, 
which is done by the recognition of self and response to non-self. The immune response has 
been divided into innate and adaptive immunity. The main components of the innate immune 
system, ready to fight microbes at the site of infection, are physical epithelial barriers, 
phagocytic leukocytes, dendritic cells, natural killer cells and circulating plasma proteins. The 
adaptive immune system is further divided into humoral immunity, mediated by antibodies 
produced by B cells, and cell-mediated immunity, mediated by T cells. CD4
+ 
T cells have 
been regarded as helper T cells, since they are required for B-cell mediated antibody 
production and effective cellular responses. CD8+ T cells differentiate into cytotoxic cells 
that are crucial in the protection from virus infections and tumour cells.  
T-cell progenitors migrate from the bone marrow to the thymus where they undergo 
differentiation. Only those that bind MHC products with low affinity survive (positive 
selection). In a second step, T-cells that are self-reactive are eliminated (negative selection). 
The selection events result in a T-cell population efficient in fighting foreign antigen and 
tolerant to self. However, in all individuals, potentially self-reactive T-cells slip through 
negative selection and enter the periphery. Peripheral tolerance is normally maintained by 
clonal elimination, anergy, and suppression of autoreactive cells by regulatory T cells
76
.  
Antigen recognition by T cells requires that the antigen has been picked up by an antigen-
presenting cell (APC) and split into small peptide fragments. The peptides then form a 
complex with MHC class I or class II proteins, which is transported to the surface of the 
APC. CD4+ T cells recognize antigen peptides bound to MHC class II molecules, whereas 
CD8+ T cells recognize antigen peptides bound to MCH class I molecules. Antigen-specific 
activation of T-cells also requires co-stimulatory signals.  
Following activation by APC, naive CD4+ T cells differentiate into different subtypes 
depending on the local cytokine environment. T helper 1 (Th1) T cells are responsible for 
cell-mediated immunity, and type T helper 2 (Th2) T cells are responsible for inducing 
antibody production by B cells and allergic responses. T helper 17 (Th17) T cells are 
produced in parallel to Th1 and also have the capacity to induce T cell mediated 
inflammation
77
. Regulatory T cells are a subpopulation of T cells that suppress immune 
responses of other cells and are important in maintaining tolerance to self antigens.  
It has been debated whether the primary mechanism of MS is inflammatory or 
neurodegenerative
78
. However, autoimmunity and inflammation are both important 
manifestations of the disease and have a central role in both the fluctuating symptoms in 
RRMS and in the accumulating CNS injury. One central hypothesis of the initiation of MS is 
that T cells specific for myelin antigens are activated in the periphery and migrate to the 
CNS, yet the mechanism of peripheral activation remains largely unknown. Once activated, 
the T cells express adhesion molecules and can actively migrate across the blood-brain 
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barrier
79-80
. In the CNS, antigen-presenting cells reactivate the T cells, which in turn leads to 
targeted destruction of the myelin sheath.  
The majority of infiltrating lymphocytes in the CNS are T cells and they include both CD4+ 
and CD8+ T cells. B cells and macrophages are also recruited and involved in the pathogenic 
process leading to the destruction of myelin sheaths. In addition, the blood brain barrier is 
compromised, which results in protein leakage into the CNS
81
.  
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2 EPIDEMIOLOGICAL STUDIES  
 
2.1 COHORT STUDIES 
Studies on how environmental and genetic factors influence MS risk are associated with 
several methodological and practical problems. The two major methods, cohort studies and 
case-control studies, have provided the majority of our current knowledge on environmental 
factors in MS.  
In a cohort study, the included study subjects are classified with regard to exposure and then 
followed over a period of time with regard to occurrence of disease. Cohort studies can be 
classified as prospective or retrospective based on when outcomes occurred in relation to the 
enrolment of the cohort. An advantage of prospective cohort studies is that a chronological 
order of events can be defined, thereby reducing the risk of recall bias and the problem of 
reverse causation.  
Due to the low incidence for many chronic diseases such as MS, a cohort study would need to 
be very large in order to generate enough cases during the course of a reasonable follow-up 
period. The need to obtain information on exposures from a large number of subjects often 
makes cohort studies very expensive to carry out.  
 
2.2 CASE-CONTROL STUDIES 
As is the case with cohort studies, case-control studies investigate the association between 
exposure and disease within a defined study base. Properly carried out, case-control studies 
provide information that mirrors what could be learned from the corresponding cohort study 
performed in the same study base, but more efficiently, using sampling. Cases that occur in 
the study population during the study period should be identified and included in the study as 
cases and controls should be randomly sampled from the study base to provide information 
on the exposure frequency in the study base. The controls may be frequency matched or 
individually matched on different characteristics of the cases (e.g. age and gender) in order to 
provide a more efficient statistical analysis. Information regarding different exposures and 
other characteristics among cases and controls is usually collected retrospectively. The 
exposure among cases is then compared to the exposure among controls in order to compute 
the OR as a measure of association. If the controls are drawn according to the principles of 
incidence density sampling, the estimated OR will be an approximation of the incidence rate 
ratio. The case-control design is well suited to investigate rare diseases or outcomes. In 
comparison with cohort studies, case-control studies are relatively inexpensive and 
considerably less time consuming.  
Bias refers to systematic errors that result in an incorrect estimate of the association between 
exposure and outcome. In case-control studies, selection bias occurs when controls are not 
representative of the population that generated the cases with regard to the exposure of 
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interest. If the response rate is less than ideal, selection bias can also be introduced if the 
likelihood of responding is related to both the exposure and the outcome. The most 
significant drawback in case-control studies with retrospectively collected exposure 
information relates to the difficulty of obtaining reliable information on previous exposures. 
Recall bias occurs when the validity of the exposure information differs between cases and 
controls. One strategy to minimize this problem is to identify and investigate the cases as 
soon as possible after disease onset. Cohort studies are usually less subject to both these 
biases but often have a low power in uncommon diseases such as MS, particularly when there 
is a long follow-up period. Optimally, results from the two approaches should be combined.  
 
2.3 STATISTICAL METHODS IN EPIDEMIOLOGICAL STUDIES 
2.3.1 Logistic regression 
Logistic regression is a frequently applied method of analysis in medical sciences. Univariate 
logistic regression is used to explore associations between one outcome and one exposure 
whereas multivariate logistic regression succeeds in controlling confounding effects since the 
effect of each exposure is unconfounded by the others when put in the same model, given no 
misclassification of confounders. Logistic regression can thus be used to estimate the 
occurrence of a disease as a function of a risk factor, taking other risk factors into account. In 
case-control studies, matching on potential confounding factors may introduce selection bias, 
which must be taken into account in the analysis. When controls are frequency matched to 
cases, the matching variables should be included in an unconditional logistic model, whereas 
conditional logistic regression, in which each matched set forms a stratum, should be used 
when controls are individually matched to cases. However, losses may be substantial when 
data contain incomplete matched sets. Data from an individual matched case-control study 
may also be analyzed with unconditional logistic regression as long as the variables used to 
form the match are included in the model.  
 
2.3.2 Measures of association 
The incidence rate ratio is defined as the ratio of the disease incidence in the exposed group 
divided by the corresponding disease incidence in the unexposed group. The OR is the 
primary measure of association in logistic regression and represents the odds that an outcome 
will occur given a particular exposure, compared to the odds of the outcome occurring in the 
absence of that exposure. The interpretation of the OR calculated from a case-control study 
depends on how the controls have been sampled. If controls are sampled according to the 
principles of incidence density sampling, the estimated OR can be interpreted as an 
approximation of the incidence rate ratio.  
An OR of 1 indicates that the odds of the outcome are equally likely for both groups under 
comparison. A 95% confidence interval is used to estimate the precision of the OR, and gives 
a range of values within which there is a 95% probability that the true value can be found. 
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2.3.3 Interaction 
Interaction between two exposures is present when the effect of one exposure on the outcome 
is different across strata of the other exposure. Interaction on an additive scale means that the 
combined effect of two exposures differs from the sum of the individual effects of the 
exposures whereas interaction on a multiplicative scale means that the combined effect 
differs from the product of the individual effects. Biologic interaction should preferably be 
assessed on an additive scale
82-83
 and the interaction can be assessed by using different 
measures such as the relative excess risk due to interaction (RERI), the attributable proportion 
due to interaction (AP), and the synergy index (SI). In the case of preventive factors, these 
should be recoded into risk factors by considering the absence of the preventive factor to be 
the cause before calculating measures of interaction on an additive scale
84
. 
 
RERI=RRAB−RRA−RRB+1 
 
where RRAB is the relative risk (RR) of disease if both factors A and B are present, RRA is the 
RR of disease if factor A but not factor B is present, and RRB is the RR of disease if only 
factor B is present. RERI can be interpreted as the excess risk due to interaction relative to the 
risk without exposure. A RERI greater than zero indicates the presence of interaction.   
 
AP=RERI/RRAB 
 
AP is the proportion of disease that is due to the interaction per se among individuals with 
both exposures. An AP greater than zero indicates the presence of interaction. 
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3 AIMS OF THESIS 
 
The overall aim of this thesis was to investigate the impact of smoking habits, and the 
potential interaction between smoking and genetic risk factors with regard to MS risk. The 
influence from environmental tobacco smoke as well as moist snuff use was also of interest. 
Each project is described in more detail below.  
Paper I: Previous studies with limited case numbers have provided evidence of an association 
between smoking and MS. We replicated the association between smoking and MS risk and 
investigated the effect of cumulative dose of smoking, stopping smoking and snuff use.  
Paper II: Use of moist snuff is common in Sweden and leads to exposure to high doses of 
nicotine. We aimed to investigate whether snuff use is associated with MS risk, taking 
smoking habits into consideration. 
Paper III: The influence of passive smoking on MS risk has been investigated in two previous 
studies, with inconsistent results. Our aim was to examine whether exposure to passive 
smoking influences MS risk among subjects who have never smoked.  
Paper IV: We investigated how age at smoking debut, smoking duration and intensity, and 
the cumulative dose of smoking and smoking cessation influence the association between 
smoking and MS risk. 
Paper V: The strongest genetic associations with MS are located within the HLA complex.  In 
this paper, we focused on the potential interaction between smoking and the MS risk HLA 
genotypes HLA-DRB1*15 and absence of HLA-A*02 alleles, with regard to MS risk.  
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4 MATERIAL AND METHODS 
 
All papers were based on data from the ongoing project Epidemiological Investigation of 
Multiple Sclerosis (EIMS). Papers II and IV also included subjects from the project Genes 
and Environment in Multiple Sclerosis (GEMS). Both EIMS and GEMS are Swedish 
population-based case-control studies, approved by the ethical review board of Karolinska 
Institutet. All participants in both studies provide written informed consent to participate.  
 
4.1 EIMS 
This project was designed as a population-based case-control study using incident cases of 
MS, with a study population comprising the Swedish population aged 16-70. Since 2005, 
cases have been recruited via hospital-based and privately run neurology units. In total, 40 
study centers, including all university hospitals, report newly diagnosed cases of MS to the 
study. Each case was examined and diagnosed according to the McDonald criteria
85
 by a 
neurologist located at the unit where the case was entered.  
For each case, two controls were randomly selected from the national population registry, 
matched by age in five-year strata, gender and residential area. If information could not be 
obtained from the control selected, then another control was chosen using the same 
principles. Personal information and information on exposures, such as tobacco consumption, 
was collected using a standardized questionnaire given to the cases shortly after they had 
received their diagnosis and sent by mail to the controls. All questionnaires were answered at 
home. Incompletely answered questionnaires were completed by mail or by telephone. All 
participants who answered the questionnaire were asked to provide a blood sample.  
The response rate for the questionnaire was approximately 98% among cases and 73% among 
controls. We received blood samples from 98% of the cases who completed the questionnaire 
and from 58% of the controls. All samples were stored at the Karolinska Institutet Biobank.  
 
4.2 GEMS 
In GEMS, prevalent cases, distinct from those in EIMS, were identified from the Swedish 
National MS-Registry. All cases fulfilled the McDonald criteria. For each case, one control 
was randomly selected from the national population register, matched for age, gender, and 
residential area at the time of disease onset. All participants filled out a questionnaire, similar 
but not identical to the EIMS questionnaire. The response rate was 82% for the cases and 
66% for the controls. 
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4.3 DATA COLLECTION 
4.3.1 Exposure Data 
Information on smoking was obtained by asking about current and previous smoking habits 
including duration of smoking, average number of cigarettes smoked per day, and type of 
cigarettes. The questions regarding snuff use were asked in a similar fashion as for smoking. 
Information on passive smoking was obtained by asking if the subject had been exposed daily 
to passive smoking at home or at work, including duration of exposure. The questions 
regarding tobacco consumption and exposure to passive smoking were identical in EIMS and 
GEMS. 
 
4.3.2 Definition of Exposures 
For each case, the time at the initial appearance of symptoms indicative of MS was used as an 
estimate of the disease onset and the year in which this occurred was defined as the index 
year. Tobacco consumption and exposure to passive smoking were only considered prior to 
the index year in the cases and during the same period of time in the corresponding controls.  
In all papers but paper V, subjects who had smoked during the index year were defined as 
current smokers, those who had stopped smoking prior to the index year were defined as past 
smokers, and subjects who had never smoked before or during the index year were defined as 
never smokers. In order to analyze the influence of a cumulative dose of smoking, we further 
categorized the smokers into groups based on the number of cigarettes smoked prior to index. 
One pack year is defined as smoking 20 cigarettes daily for one year.  
In paper V, current smoking was defined as above. However, subjects who had stopped 
smoking within five years prior to index were excluded in paper V whereas subjects who had 
never smoked or had stopped smoking more than five years prior to index were defined as 
non smokers.  
Subjects who had used snuff before or during the index year were defined as snuff users. The 
subjects were then categorized into groups based on the duration of snuff use (years) and the 
cumulative dose of snuff (packet-years) before index. One packet-year is the equivalent of 
consuming one packet of snuff daily for one year. 
 
4.4 GENOTYPING 
The blood samples in EIMS were genotyped with sequence-specific primers using Olerup 
SSP
TM 
HLA kits
86
. After polymerase chain reaction (PCR) amplification, the products were 
run on an agarose electrophoresis gel stained with GelRed, and visualized on a UV-table. The 
wells with a positive signal were interpreted according to a chart and the HLA-DRB1 and 
HLA-A genotypes were established at the two-digit level. Genotypes from EIMS were used 
in paper V.   
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4.5 STATISTICAL  ANALYSIS 
In all papers, logistic regression was performed to assess associations between exposure and 
MS risk, using Statistical Analysis System (SAS) version 9.2.  
The lifestyle- and environmental factors investigated in this thesis were considered prior to 
the index year in the cases and during the same period of time in the corresponding controls. 
In principle, this calls for a matched analysis. We performed both matched analyses based on 
all available case-control pairs or triplets and unmatched analyses based on all available 
subjects. In all papers, the results from the unmatched analyses were in close agreement with 
those from the matched analyses but had a higher degree of precision. Matching led to a loss 
of cases and controls in the analyses which is why the results from the unmatched analyses 
were presented in the papers. 
In paper IV, a trend test for a dose response relationship regarding cumulative dose of 
smoking and risk of MS was performed by using a continuous variable for cumulative dose 
of smoking, expressed as pack-years, in a logistic regression model. In order to determine 
whether intensity or duration of smoking contributes most to the risk of MS, we examined 
the components comprising pack-years in the same logistic regression model.  
In paper V, the linkage disequilibrium (LD) between HLA-A*02 and HLA-DRB1*15 was 
estimated in Unphased 3.0 (Dudbridge, 2003) by considering presence and absence of 
HLA-A*02 and HLA-DRB1*15 alleles. We applied multivariate logistic regression in order 
to distinguish specific HLA genotypes contributing to MS susceptibility, using a model with 
all HLA-DRB1 and HLA-A alleles with frequencies above 10% among controls. Alleles with 
a frequency of less than 10% among controls were grouped together into DRB1X and AX, 
respectively. We then investigated the possible gene-gene interaction between alleles that had 
a significant influence on MS risk and also the possible interaction between these alleles and 
smoking. The interaction analyses were performed using departure from additivity of effects 
and were evaluated by calculating AP together with 95% confidence intervals (CI).  
 
4.6 CONFOUNDING FACTORS 
In the context of unmatched logistic regression, the analyses were adjusted for the matching 
variables. All analyses were adjusted for ancestry. Assessment of ancestry was based on 
whether the subject was born in Sweden or not, and whether either of the subject’s parents 
had immigrated to Sweden. A subject who was born in Sweden, whose parents had not 
immigrated, was classified as Swedish. When EIMS and GEMS data were analyzed together, 
adjustment was made for study.  
All analyses were further adjusted for a broad range of potential confounding variables. In 
paper I, adjustments were made for educational level (university degree or not), BMI at 
inclusion in the study (<19 or >19 kg/m
2
), parity (yes or no), and oral contraceptive use (ever 
or never). BMI was obtained by dividing self-reported weight in kilograms by self-reported 
height in meters squared. However, these factors had minor influence on the results and were 
not adjusted for in the final analyses.  
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In paper II, the final analyses were adjusted for educational level, and when appropriate, 
smoking habits (0, 1–5, 6–10, 11–15 or >15 pack years of smoking). Adjustments were also 
made for heredity (having a first- or second-degree relative with MS or not), passive smoking 
(yes or no), BMI at age 20 years (<27 or >27 kg/m
2
), and socioeconomic status. Detailed 
information was obtained regarding current and previous professions and work places. Each 
occupation was given an occupational class code according to a Swedish classification 
system of occupations adjusted to international standards
87
. Based on the occupational codes, 
study subjects were classified according to occupational class (skilled and unskilled workers, 
assistant, intermediate, and higher non-manual employees). These factors had minor 
influence on the results and were not included in the final analyses. 
In paper III, which comprised never smokers, the final analyses were adjusted for heredity, 
educational level, socioeconomic status, BMI at inclusion in the study, self-reported history 
of mononucleosis (yes or no),  Epstein-Barr virus-determined nuclear antigen 1 (EBNA1) 
immunoglobulin G (IgG) titres, UVR exposure habits, and vitamin D status. EBNA1 IgG and 
vitamin D were measured in samples included between April 2005 and December 2009. 
EBNA1 IgG levels were measured with ELISA kits and categorized into high level (more 
than the median among controls), low level (less than the median of controls), or unknown 
level. Based on three questions regarding UVR exposure where each answer alternative was 
given a number ranging from 1 (the lowest exposure) to 4 (the highest exposure), we 
constructed an index by adding the numbers together and thus acquired an index value 
between 3 and 12. UVR exposure was dichotomized into high or low exposure (index values 
more or less than 6). Vitamin D status was measured as 25(OH)-vitamin D in plasma and 
categorized into sufficient levels (50 nmol/l or higher), vitamin D deficiency (less than 50 
nmol/l), or unknown.  
The analyses on smoking and MS risk in paper IV were adjusted for a broader range of 
potential confounding factors than the analyses in paper I; heredity, educational level, BMI at 
age 20 years, UVR exposure habits during the last 5 years, self-reported history of infectious 
mononucleosis, passive smoking, and snuff use (yes or no). These factors had minor 
influence on the results of the study. Only passive smoking was retained in the final analyses.  
In paper V, further adjustment for educational level, HLA-DRB1*07, HLA-DRB1*X, and 
HLA-A*03 status only marginally influenced the results and these factors were not retained 
in the final analyses.  
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5 RESULTS AND INTERPRETATION 
 
5.1 PAPER I 
Our analyses of smoking and MS risk included 902 cases and 1855 controls. The study 
period for this report was April 2005 to October 2008. Compared with never smokers, the OR 
for MS among smokers was 1.5 (95% CI 1.3-1.8) which was in accordance with the result of 
a pooled analysis of nine previous studies on smoking and MS risk. We thus replicated the 
finding of an association between smoking and MS risk, and found clear evidence of a dose-
response correlation between cumulative dose of smoking and the risk of developing the 
disease (p value for trend <0.0001). We further observed that the increased risk of MS 
associated with smoking abates a few years after smoking cessation (table 1).  
 
Table 1. Adjusted OR with 95% of developing MS for different categories of smokers 
compared with never smokers. 
Smoking ca/co* OR (95% CI) 
Never smoker 385/967 1.0  (reference) 
Ever smoker 517/888 1.5 (1.3-1.8) 
Current smoker 322/530 1.6 (1.3-1.9) 
Past smoker 195/358 1.4 (1.1-1.8) 
5 years since smoking cessation 74/107 1.5 (1.1-2.0) 
>5 years since smoking cessation 120/251 1.0 (0.8-1.3) 
 
* number of exposed cases and controls 
# adjusted for age, gender, residential area, and ancestry.  
 
Both among ever and never smokers, snuff use was associated with decreased risk of 
developing MS. However, the number of exposed subjects was limited. All analyses were 
adjusted for age, residential area and ancestry, and when appropriate, gender.  
 
5.2 PAPER II 
Since a large proportion of the Swedish population uses moist snuff, which leads to exposure 
to high doses of nicotine, we set out to investigate the impact of snuff on MS risk using both 
EIMS and GEMS data (7883 cases and 9437 controls). Compared with subjects who had 
never used snuff, the OR of developing MS was 0.83 (95% CI 0.75-0.92) for snuff users, and 
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a significant trend showed an inverse risk of MS with higher dose of snuff use (table 2).  
 
Table 2. OR with 95% CI of developing MS for snuff users compared with subjects who 
have never used moist snuff, by cumulative dose of snuff use.  
Packet-years ca/co* OR (95% CI)# OR (95% CI)¤ p p value for trend 
0 7095/8363 1.0 (reference) 1.0 (reference)   
<5 516/642 0.95 (0.83–1.07) 0.85 (0.75–0.97) 0.02  
5-10 181/251 0.84 (0.68–1.03) 0.77 (0.63–0.95) 0.01  
>10 91/181 0.59 (0.45–0.77) 0.57 (0.44–0.74) <0.0001 <0.0001 
* exposed number of cases and controls 
# adjusted for age, gender, residential area, educational level, and ancestry. 
¤ adjusted for age, gender, residential area, educational level, ancestry, and smoking.  
 
The results remained similar but had a lower degree of precision when the analysis was 
restricted to never smokers. There were no gender differences. We further observed that 
subjects who combined smoking and snuff use had a significantly lower risk for MS than 
smokers who had never used moist snuff (table 3). 
 
Table 3. OR with 95% CI of developing MS for subjects with different combinations of 
smoking and snuff use. 
Tobacco use  ca/co* OR (95% CI) P 
Never 3286/4679 1.0 (reference)  
Ever smoking (no snuff use) 3704/3600 1.49 (1.40–1.59) <0.0001 
Current smoking (no snuff use) 2313/2161 1.56 (1.45–1.67) <0.0001 
Past smoking (no snuff use) 1391/1439 1.35 (1.24–1.47) <0.0001 
Snuff use (no smoking) 223/392 0.75 (0.63–0.90) 0.002 
Snuff use and ever smoking 668/765 1.19 (1.06–1.34) <0.0001 
Snuff use and current smoking 359/344 1.42 (1.21–1.65) <0.0001 
Snuff use and past smoking 309/421 1.03 (0.88–1.20) 0.7 
* exposed number of cases and controls 
# adjusted for age, gender, residential area, educational level, and ancestry. 
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5.3 PAPER III 
When exploring the possible influence of passive smoking on MS risk, we included only 
subjects who had never smoked (695 cases and 1635 controls). Compared with those who 
had never been exposed to passive smoking before the index year, the OR of developing MS 
was 1.3 (95% CI 1.1-1.6) for those who had been exposed. We observed a significant trend 
that showed higher risk of MS with longer duration of exposure (p value 0.003). When the 
duration of exposure was twenty years or longer, the OR of developing MS was 1.8 (95% CI 
1.2-2.6) compared with subjects who had never been exposed (table 4). The analyses were 
adjusted for a broad range of potential confounding variables. 
 
Table 4. OR with 95% CI of developing MS for subjects exposed to passive smoking, 
compared with those who have never been exposed, by duration of exposure. All subjects 
were never smokers. 
 
Passive smoking ca/co* OR (95% CI)# OR (95% CI)¤  
Never 423/1094 1.0 (reference) 1.0 (reference) 
<10 years 89/182 1.3 (1.0-1.8) 1.4 (1.0-2.0) 
10-20 years 133/295 1.3 (1.0-1.7) 1.4 (1.0-1.8) 
>20 years 50/84 1.8 (1.2-2.6) 1.8 (1.2-2.7) 
  0.003 0.003 
 
* exposed number of cases and controls 
# adjusted for age, gender, residential area, and ancestry. 
¤ adjusted for age, gender, residential area, ancestry, EBNA1 titres, a history of infectious mononucleosis, vitamin D status, UVR exposure 
habits, heredity, educational level, socioeconomic status, and body mass index. 
 
5.4 PAPER IV 
Our analyses of smoking and MS risk, based on EIMS and GEMS, included 7883 cases and 
9264 controls. The study period for EIMS was April 2005 to March 2012, whereas study 
participants in EIMS were recruited between November 2009 and November 2011. We 
aimed to investigate aspects of the association between smoking and MS risk that had 
previously been investigated only to a limited extent. Compared with subjects classified as 
never smokers, ever smokers had an increased risk of developing MS (OR 1.5, 95% CI 1.4-
1.6, p<0.0001). A trend test for a dose response relationship between smoking and MS risk, 
using a continuous variable for cumulative dose of smoking, rendered a p value of <0.0001. 
When duration and intensity of smoking were mutually adjusted for one another in the same 
multivariate model, both factors contributed independently to the risk of MS (p values 
<0.0001). 
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Age at start of regular smoking did not affect the risk of developing MS (table 5; figure 4). 
We further observed that the detrimental effect of smoking abates a decade after smoking 
cessation regardless of age at exposure (table 5; figure 4) and regardless of the cumulative 
dose of smoking (table 6; figure 5). 
 
Figure 4. OR of developing MS among smokers and past smokers, compared to never 
smokers, by age at starting smoking. 
 
 
Figure 5. OR of developing MS among smokers and past smokers, compared to never 
smokers, by cumulative dose of smoking 
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5.5 PAPER V 
Our analysis included 843 cases and 1209 controls, all of whom had provided blood samples. 
The strongest genetic associations with MS were those for the HLA-DRB1*15 allele and 
absence of the HLA-A*02 allele, and these were included in the interaction analysis. The 
observed LD between DRB1*15 and HLA-A*02 was low (r
2
<0.0005). An interaction was 
observed between smoking and the genetic risk factors presence of HLA-DRB1*15 and 
absence of HLA-A*02, with regard to MS risk. Smokers with neither of the genetic risk 
factors had an OR of 1.4 (95% CI 0.9-2.1), compared to non-smokers without genetic risk. 
Both genetic risk factors among non-smokers rendered an odds ratio of 4.9 (95% CI 3.6-6.6) 
whereas the OR was 13.5 (95% CI 8.1-22.6) among current smokers with the same genotype 
(table 7; figure 6). All analyses were adjusted for age, gender, residential area, and ancestry. 
 
Table 7. OR with 95% CI of developing MS for subjects with different combinations of 
smoking habits and the genetic risk factors carriage of HLA-DRB1*15 and absence of HLA-
A*02, compared with non smokers carrying none of the genetic risk factors. 
 
HLA-DR15+ HLA-A*02- Smoking ca/co* OR (95% CI)# p-value 
- - - 111/376 1.0 (reference)  
- + - 137/301 1.6 (1.2-2.1) 0.003
 
+ - - 152/140 3.7 (2.7-5.1) <0.0001 
+ + - 192/136 4.9 (3.6-6.6) <0.0001 
- - + 41/104 1.4 (0.9-2.1) 0.1 
- + + 63/81 2.7 (1.8-4.0) <0.0001 
+ - + 60/49 4.3 (2.8-6.6) <0.0001 
+ + + 87/22 13.5 (8.1-22.6) <0.0001 
 
* number of exposed cases and controls. 
# analyses were adjusted for age, gender, residential area, and ancestry.  
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Figure 6. OR with 95% CI of developing MS for subjects with different combinations of the 
genetic risk factors carriage of HLA-DRB1*15 and absence of HLA-A*02, compared with 
non smokers carrying none of the genetic risk factors, among smokers and non smokers. 
Statistics are shown in table 7.  
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6 DISCUSSION 
Our finding of an association between smoking and increased MS risk is consistent with 
previous findings
53-60
. However, our study is the largest to date, and we had the opportunity 
to investigate this association in detail. From a clinical point of view, our results support the 
view that abstinence from smoking should be recommended to those at risk of developing 
MS such as children of patients with MS. The results in paper IV show that even smoking a 
few cigarettes a day for a longer period confers an increased MS risk while stopping smoking 
at any age can lower the risk of MS regardless of previous smoking habits.  
Of particular interest is also the observation that age at exposure does not affect the increased 
risk of MS associated with smoking. Both family studies and migration studies suggest that 
the influence of environmental factors contributes to MS at different age periods. The effects 
of vitamin D deficiency are likely to have an impact early in life, whereas EBV infection 
probably influences risk during adolescence or early adulthood
88
. High BMI during 
adolescence has been associated with increased risk of developing MS later in life
72-73
. 
Certain aspects of adolescence thus seem to be critical regarding the impact of several 
environmental factors on MS risk. Smoking, on the contrary, affects MS risk regardless of 
age at exposure, and the detrimental effect abates a decade after smoking cessation.  
Our finding of an interaction between smoking, HLA-DRB1*15 and the absence of HLA-
A*02 in paper III may represent a breakthrough in the process of understanding the influence 
of smoking on MS risk. The molecular pathways responsible for the observed association 
between smoking and MS are not yet known, but a variety of mechanisms have been 
suggested to explain the association. We hypothesize that the mechanism linking smoking 
and passive smoking to MS susceptibility involves autoimmunity against proteins with post-
translational modifications that are cross-reactive with CNS antigens. Since smoking, but not 
use of oral tobacco in the form of moist snuff, increases MS risk, the critical effects of 
smoking and passive smoking is likely to be caused by irritation in the lungs. Exposure to 
tobacco smoke results in increased pro-inflammatory cell activation in the lungs
 
and post-
translational modifications of proteins
89
, which may break self-tolerance
90-91
. Autoimmune 
memory cells are present and available for triggering in the lungs. In EAE studies, these cells 
strongly proliferate after local stimulation of the lungs and, after assuming migratory 
properties, reach the CNS, with inflammation as a consequence
80
.  
The main function of the HLA gene products is antigen presentation to T cells. The amino 
acid sequences of HLA class I and II alleles determine to a large extent the ability to 
respond to an antigen. Preferences in peptide binding by allelic variants of class I and II 
molecules are likely to be critical for the influence of HLA on autoimmune diseases. With 
regard to risk of rheumatoid arthritis, an interaction has been identified between smoking, 
HLA alleles, and autoimmunity to post-translationally modified proteins
92
. This is 
consistent with class II allele specific recognition of particular altered self peptides in the 
lungs, with ensuing organ-specific inflammatory disease depending on preferential peptide 
binding by allelic variants of class II molecules. We thus hypothesize that smoke-induced 
lung-irritation in the context of MS risk HLA genes may post-translationally modify 
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peptides cross-reactive with CNS antigens, promoting a CNS-directed autoaggressive 
immunity that results in MS. 
Our study of interaction between smoking and genotype emphases the value, and 
sometimes need, to include data on environmental exposures in genetic analyses of 
complex diseases, since it has now been demonstrated that the strongest genetic risk factors 
for MS are significantly influenced by the presence of smoking in the population at risk, 
and vice versa. 
Although the net effect of smoking is pro-inflammatory, there is increasing evidence that 
smokers have a lower incidence of several inflammatory diseases, such as ulcerative colitis 
and sarcoidosis
93
. The protective effect has been attributed to the ability of nicotine to 
dampen inflammation
94
. In paper II, the finding that snuff use is inversely associated with MS 
may have practical implications in counseling MS patients who smoke. Circumstantial 
evidence suggests that smoking not only increases the risk of developing MS, but also leads 
to an aggravated disease course
95-96
. Hence, stopping smoking through the use of alternative 
nicotine routes may be advised.  
Moist snuff contains a number of different substances apart from nicotine and any of them 
could theoretically be involved in the protective effect. However, nicotine stands out as the 
main candidate in view of numerous studies on its immunomodulatory effects. Nicotine may 
exert systemic effects on the immune system by inhibiting the production of pro-
inflammatory cytokines from immune cells, such as macrophages, via the alpha7 subunit of 
the acetylcholine nicotinic receptor
97
. Since MS is most likely driven by systemic immune 
responses targeted at the CNS, nicotine may also be involved in this disease, consistent with 
the apparent lower incidence in long term snuff users.  
The design of EIMS and GEMS offered several methodological advantages. Cases in both 
studies were identified using strict diagnostic criteria and the possibility of misclassification 
of MS diagnosis was negligible. Another strength was the large number of participants.  
Our studies also have some limitations. The recruitment of cases and controls may introduce 
selection bias. In EIMS, the proportion of responders with regard to participation in the study 
was 91% for cases and 69% for controls and in GEMS, the proportion of responders was 82% 
for cases and 66% for controls. In Sweden, there is equal access to publicly sponsored health 
care for all residents, and patients with MS are cared for by neurologists. In EIMS, there are 
40 reporting neurology clinics, including all university hospitals in Sweden. However, due to 
shortage of personnel at the clinics, there may have been patients who never received an 
invitation to participate in the study. Some of the incident cases unidentified in EIMS would 
instead have been identified in GEMS, in which all prevalent cases registered in the Swedish 
National MS-Registry were asked to participate. We consider it unlikely that the unidentified 
cases would be related to the exposures studied in the present thesis. We thus believe that 
misclassification of disease will only bias the observed results to a minor or negligible extent.   
A potential selection bias may result from the relatively high proportion of non-responders 
among the controls. The loss of controls was however less than stated above, since some non-
responders among the invited controls were likely not part of the study base since the 
proportion of immigrants is high among the non-responders and an inclusion criteria of the 
study is knowledge of the Swedish language. However, this bias is probably modest since life 
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style habits such as prevalence of smoking and snuff use among the controls was consistent 
with that expected for the general population in similar ages
98
. 
Only controls who had responded to the questionnaire were asked to provide a blood sample, 
and 58% of these controls consented to do so. There were no differences with respect to age, 
gender, residential area or smoking habits between those who provided blood and those who 
did not, indicating that selection did not take place in this step. We consider it unlikely that 
our main finding of an interaction between smoking and HLA genotype would be affected by 
bias to a large extent, especially since such a bias would then depend on HLA types. 
Both EIMS and GEMS were designed as population-based case-control studies, in which 
information regarding exposures and lifestyle factors was collected retrospectively. On 
account of this design, recall bias may have occurred, thereby introducing systematic error in 
the calculation of the association between tobacco and MS risk. In order to minimize recall 
bias, EIMS primarily included cases who had received the diagnosis within the past year. The 
rationale for only including cases of recent onset was that these subjects were considered 
unlikely, during the short duration of their illness, to have changed their habits on account of 
the illness, avoiding error introduced by the endorsement of current rather than former habits.  
In GEMS, in which the mean disease duration is about 17 years, the probability of recall 
errors is higher. MS-related declines in memory and cognition may have resulted in a greater 
degree of error, in the form of incorrect classification of exposure.  
In both studies, we took great care to obtain information in an identical way for the cases and 
the controls. The questionnaire contained a wide range of questions regarding many potential 
environmental risk factors and no section in the questionnaire was given prime focus. 
Furthermore, when EIMS and GEMS were analyzed separately, the association between 
smoking and MS was similar in both studies. Consequently, the potential recall bias is likely 
to be small. When paper I was published, the relationship between snuff use and MS risk had 
not previously been investigated, and the quality of the reported information on snuff use 
does probably not differ between cases and controls. In paper III, almost all subjects who 
were classified as exposed to passive smoking reported that they had been exposed at home, 
which is relatively easy to remember. Recall bias is probably small in this study, and there is 
no reason to believe that potential recall problems should differ between cases and controls.  
Our analyses were adjusted for a number of potential confounding factors. However, as with 
most epidemiological studies, we cannot completely rule out that our findings could be due to 
residual confounding or unknown confounding factors.  
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7 SUMMARY OF FINDINGS 
 Smoking and exposure to passive smoking increase the risk of developing MS. 
 
 Snuff use is associated with decreased MS risk. 
 
 A dose-response correlation exists between cumulative dose of smoking and the risk 
of developing the disease. 
 
 Duration and intensity of smoking contribute independently to the risk of MS. 
 
 The risk of MS increases with longer duration of exposure to passive smoking. 
 
 Smoking affects MS risk regardless of age at exposure. 
 
 The detrimental effect of smoking abates a decade after smoking cessation. 
 
 A substantial interaction was observed involving smoking and the genetic risk factors: 
presence of HLA-DRB1*15 and absence of HLA-A*02. 
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8 CONCLUDING REMARKS 
In yet unknown ways, MS develops from a combination of a complex genetic predisposition 
and environmental factors. Interactions between different genetic loci as well as between 
genes and environmental factors may further add to the complexity of disease susceptibility. 
Over recent years, GWAS have identified a large number of risk loci that influence disease 
susceptibility
18-19
. The contribution of lifestyle and environmental factors is more difficult to 
study. However, it is important to identify these factors as they are potential targets for 
prevention and may also lead to hypothesis on critical pathogenic events.  
The main aim of this thesis was to enhance the understanding of the impact of tobacco on MS 
risk. Although our findings will hopefully have made a contribution to the exploration of the 
relationship between tobacco and MS, much remains to be done. We hope that our finding of 
an interaction between smoking and HLA genotype can provide important guidance for 
further studies leading to an understanding of the mechanisms by which smoking and passive 
smoking increase the risk of developing MS. A replication of the gene-environment 
interaction in other populations, or an observation of an interaction between passive smoking 
and HLA genotype, would support our hypothesis that priming of the immune response in the 
lungs may subsequently lead to MS in people with a genetic susceptibility to the disease.  
Susceptibility to MS results from the combined effects of many different combinations of risk 
alleles. Each individual locus is probably neither necessary nor sufficient for the development 
of MS, but an accumulation of risk alleles may generate a high level of disease risk. It would 
therefore be of interest to take other genetic loci into consideration when investigating the 
association between smoking and HLA genotype with regard to MS risk.  
Paper III demonstrates that passive smoking is associated with an increased risk for MS, 
suggesting that also lower degrees of lung irritation may contribute to the triggering of MS. 
Further studies would be valuable in order to investigate the impact of other forms of lung 
irritation, such as air pollution, in the etiology of MS. 
Recent studies show that the immune system can be significantly regulated by the vagus 
nerve via the peripheral release of acetylcholine
97
. The neurotransmitter also functions as an 
immune cytokine that inhibits the release of pro-inflammatory cytokines from immune cells, 
such as macrophages, through a mechanism dependent on the alpha7 nicotinic receptor. 
Nicotine, a more selective cholinergic agonist, is more efficient than acetylcholine at 
attenuating the production of pro-inflammatory cytokines
99-100
. However, the development of 
nicotine as a therapeutic tool is not an option due to lack of pharmacological specificity, 
toxicity-related side effects and unknown long-term effects on human health. Nevertheless, 
selective agonists for the alpha7 nicotinic receptor could represent a pharmacological strategy 
to control a variety of pro-inflammatory cytokines, and may prove beneficial in several 
inflammatory and neurodegenerative disorders
100-101
.  
 36 
 
Advances in our understanding of environmental risk factors can lead to avenues of research 
exploring how these factors may play a role in the pathogenesis of the disease. It has become 
increasingly clear that the risk conveyed by an environmental factor may substantially differ 
depending on genetic background. Future studies must resist the temptation to investigate 
environmental risk factors for MS in isolation, since interactions with both other 
environmental influences and an individual's genetic background are likely to contribute to 
MS development.  
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